Cerus gets $248M BARDA contract for RBC program; EU CE Mark review denied

CERUS CORP

New BARDA contract valued up to $248M to support U.S. INTERCEPT RBC system development and PMA submission; $32.1M awarded for base period.
CE Mark review in Europe closed without approval due to insufficient impurity profile data; company assessing strategy for future filing.
RedeS Phase 3 trial enrolling at two new sites; timing of completion and PMA submission under assessment due to later-than-expected site activation.
Company believes positive ReCePI trial data could support broader indication in a future EU CE Mark submission.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.